spacer
home > ebr > autumn 2009 > designer therapeutic proteins
PUBLICATIONS
European Biopharmaceutical Review

Designer Therapeutic Proteins

 

Botulinum neurotoxin has achieved celebrity status through its use in cosmetic treatment. The most lethal toxin known in nature, it is also a notorious cause of the deadly food poisoning, botulism. Lay patients are less aware, however, that its ability to relax and paralyse muscles has many therapeutic applications.

It is not a perfect therapy, despite being used to treat inappropriate or excessive contractions of muscles throughout the body. Botulinum neurotoxin remains a highly toxic substance and a recognised bioterrorism threat, and it is only safe when used in low nanogram quantities. Since the toxin evolved to target nerve cells specifically, its effects are limited to conditions involving peripheral nerve transmission, and muscle relaxation in particular.

Both the toxic and therapeutic effects of botulinum neurotoxin arise from the same property: the ability to inhibit neurotransmitter release from nerve cells. Imagine if botulinum neurotoxinís ability to target and inhibit nerve cell secretions could be widened to other cell types, while rendering it non-lethal.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Keith Foster is Founder and Head of Technology Development at Syntaxin Ltd. An internationally recognised expert on botulinum neurotoxins, he led the team at the UK Health Protection Agency that developed the proprietary technology that is the basis of Syntaxin, and co-led the spin-out of Syntaxin from the HPA in November 2005. He is an inventor on 16 international patent families with 29 granted patents worldwide, including the core patents underpinning Syntaxinís neurotoxin technology, and has published over 40 scientific papers. Keith has over 25 yearsí management experience in pharmaceutical R&D, including positions with SmithKline Beecham and Ipsen. He has an MA in Natural Science from the University of Cambridge and a PhD from the University of London.
spacer
Keith Foster
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACRO Releases Diversity and Inclusion Principles Statement in Support of More Diverse Clinical Trials


More info >>

White Papers

Spotlight on Quality in Study Startup

Oracle Health Sciences

This white paper addresses the growing interest in quality in clinical trial execution and how workflows play an essential role by building in the steps needed to comply with TMF guidelines, reducing downstream problems. This proactive strategy limits issues caused by siloes, yielding process improvements measurable by performance metrics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement